Pitney Bowes Inc., operates as a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to small businesses, large enterprises, and government entities around the world. It operates through SendTech Solutions and Presort Services segments. The SendTech Solutions segment provides physical and digital shipping and mailing technology solutions, and other applications for sending, tracking and receiving of letters, parcels and flats, supplies, and maintenance services, as well as financing alternatives to finance equipment and product purchases. The Presort Services segment offers mail sortation services, which allow clients to qualify volumes of first-class mail, marketing mail, marketing mail flats, and bound printed matter for postal workshare discounts. It markets its products, solutions, and services through direct and inside sales force, global and regional partner channels, direct mailings, and digital channels. The company was formerly known as Pitney Bowes Postage Meter Company. Pitney Bowes Inc. was incorporated in 1920 and is headquartered in Stamford, Connecticut.

Pitney Bowes Inc.

In a report released today, John Hester from Bell Potter maintained a Buy rating on Paradigm Biopharmaceuticals, with a price target of A$0.42. Acc...

Bell Potter Sticks to Their Buy Rating for Paradigm Biopharmaceuticals (PBIGF)

Pitney Bowes (($PBI)) has held its Q2 earnings call. Read on for the main highlights of the call. Pitney Bowes’ latest earnings call struck a cauti...

Pitney Bowes Earnings Call: Debt Cuts, Margins, Headwinds

Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Pitney Bowes (PBI), Woodward (WWD) and Mercu...

Analysts Have Conflicting Sentiments on These Industrial Goods Companies: Pitney Bowes (PBI), Woodward (WWD) and Mercury Systems (MRCY)

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has shared an announcement. Paradigm Biopharmaceuticals has updated the market on changes to its issued c...

Paradigm Biopharmaceuticals Cancels Shares Under Employee Scheme Buy-Back

Paradigm Biopharmaceuticals ( ($AU:PAR) ) has issued an update. Paradigm Biopharmaceuticals has received a combined $5.75 million in cash through A...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PBI	$16.42	0.00%	1.86M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PBI	$16.42	0%	1.86M
3
4
5
6

PBI

Get Pitney Bowes Inc. Data in Excel

Get Pitney Bowes Inc. Data in Excel